Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $27.40.

A number of equities research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a report on Friday, January 17th. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research lowered their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $12.00 price target on shares of Outlook Therapeutics in a report on Friday, January 17th.

Outlook Therapeutics Stock Up 5.7 %

Outlook Therapeutics stock opened at $1.84 on Friday. Outlook Therapeutics has a 52 week low of $0.87 and a 52 week high of $12.85. The company’s 50 day moving average price is $1.86 and its two-hundred day moving average price is $4.56. The stock has a market cap of $58.84 million, a P/E ratio of -0.21 and a beta of 0.58.

Outlook Therapeutics (NASDAQ:OTLK) last posted its earnings results on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.06. On average, equities analysts anticipate that Outlook Therapeutics will post -2.25 EPS for the current year.

Institutional Investors Weigh In On Outlook Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. raised its holdings in Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock valued at $275,000 after acquiring an additional 18,287 shares during the period. State Street Corp raised its holdings in Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after acquiring an additional 21,201 shares during the period. Geode Capital Management LLC raised its holdings in Outlook Therapeutics by 49.2% during the 3rd quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after acquiring an additional 112,812 shares during the period. Barclays PLC raised its holdings in Outlook Therapeutics by 677.4% during the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after acquiring an additional 18,249 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in Outlook Therapeutics during the 2nd quarter valued at $232,000. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.